Course Provider
Learning Objectives
Upon completion of this activity, participants should be better able to describe barriers to timely access to hematologic malignancy care and apply interprofessional strategies for addressing factors impeding optimal care
Upon completion of this activity, participants should be better able to assess the role of molecular, predictive, and prognostic factors in guiding treatment decisions for patients with hematologic malignancies
Upon completion of this activity, participants should be better able to differentiate targeted agents and immunotherapies based on mechanism of action, new safety and efficacy data, and place in therapy
Upon completion of this activity, participants should be better able to implement evidence-based strategies for individualizing patient care and treatment in the federal and public health settings